Biologics

Insurers Push for Cheaper, Untested Eye Treatment

August 26, 2021

Injecting a syringe of an unapproved treatment into a patient’s eyeball would be a nightmare scenario for most ophthalmologists. But that is what many major insurance companies are now suggesting doctors do.

Commonsense State Rules Ease Access to Biosimilars

August 11, 2021

Health care in the United States has quietly turned a big corner. Just as the FDA approved its first interchangeable biosimilar, Oklahoma became the 50th and final state where pharmacists can substitute these lower-cost versions of biologic drugs.

Embracing Biosimilars

July 13, 2021

I know some people who are brand loyal because they are hesitant to change. I, however, am not one of them. And I take that approach in prescribing biologics and biosimilars for my patients, too.

ICER Crosses the Center Line

July 9, 2021

The admonition to the Institute for Clinical and Economic Review’s Beacon Hill economists should be quite simple: “Stay in your lane.”

How Biologics Transformed Care for MS Patients

May 19, 2021

For 20 years there wasn’t a single medication I could prescribe to help my patients overcome multiple sclerosis, a disease that gradually robbed them of their strength, vision, coordination, and also memory and thinking abilities.